

**Cancerogenesis and neoplasia.  
Oncology.**

Markéta Hermanová

# Neoplasia, tumor - definition

- „abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and persists after cessation of the stimuli which evoked the change“ (Willis)
- Genetic and regulatory changes → functional dysregulation of proliferation that becomes autonomous + failure of the process of natural cell death
- Clonal proliferation/expansion of the transformed cell (tumors are monoclonal)
- Sporadic mutations in somatic cell or germline mutations


# Carcinogenesis

- Multistep process at both phenotypic and genetic levels
- Nonlethal genetic damage (or mutation)
  - exogenic factors (radiation, chemicals, viruses,...)
  - endogenic factors (toxic radicals, genome instability, failure of DNA damage repair, chromosomal rearrangements,...)
  - germline mutations
- Clonal expansion of a single precursor cell that has incurred the genetic damage (tumors are monoclonal)


# Targets of genetic damage

- The growth-promoting protooncogenes  
(dominant; support of cell proliferation)
- The growth-inhibiting tumor suppressor genes  
(recessive; inhibition of growth)
  - Gatekeepers (p53, RB)
  - Caretakers (genes involved in maintenance of genome integrity and DNA repair)
- Genes regulating the programmed cell death  
(apoptosis)
- Genes involved in DNA repair
- Oncogenic microRNA

# Molecular basis of cancer



# The role of tumor suppressor p53



# Composition of tumors:



- **Parenchyma** (proliferating neoplastic cells)
- **Stroma** (connective tissue and blood vessels, source of mediators promoting the tumor growth and angiogenesis)
- (Cancer stem cells – tumor initiating cells)
  
- Cross-talk between stroma and parenchyma
- Tumors with abundant parenchyma: soft and fleshy
- Tumors with abundant collagenous stroma – with desmoplastic stroma: stony hard - scirrhous

# Cancer stem cells – tumor initiating cells

- subpopulation of tumor cells that possess self-renewal properties and are able to differentiate into multiple cell types providing various cell lines, which enable the progression of an incipient tumor
- resistant to conventional therapies
- a source of the tumor relapse after eradication of the bulk of the tumor
- oncological research focused in further understanding of CSCs and in the development of therapeutic strategies targeted at CSCs.



# Cancer stem cell therapy



# Classification of tumors


- According to their biological behavior:
  - Benign
  - Semimalignant and potentially malignant
  - Malignant
- Histogenetic classification of tumors (morphologic classification according to tissue of origin)
  - epithelial
  - mesenchymal
  - neuroectodermal
  - germ cell
  - mixed

<b>Feature</b>	<b>Benign tumors</b>	<b>Malignant tumors</b>
<b>Growth rate</b>	slow	Relatively rapid
<b>Mitoses</b>	Infrequent	Frequent and often atypical
<b>Differentiation</b>	Good	Variable, often poor
<b>Nuclear morphology</b>	Often normal	Usually hyperchromatic, irregular outline, multiple nucleoli and pleomorphic
<b>Invasion</b>	No	Yes
<b>Metastases</b>	Never	Frequent
<b>Border</b>	Often circumscribed or encapsulated	Often poorly defined, irregular
<b>Necrosis</b>	Rare	Common
<b>Ulceration</b>	Rare	Common on skin and serous surfaces
<b>Growth on skin or mucosal surfaces</b>	Often exophytic	Often endophytic

# Semimalignant and potentially malignant tumors

- Different levels of loss of differentiation
- Tissue and cellular atypia
- Usually increased proliferation, atypical mitoses
- Invasive, poorly demarcated; sometimes partially expansively growing
- No metastases
- *Basalioma of the skin*
- Differentiated
- No tissue and cellular atypia
- No atypical mitoses
- Expansively growing, often encapsulated
- Sometimes metastases
- *Pleomorphic adenoma of salivary glands*

# Comparison between benign leiomyoma and malignant leiomyosarcoma



# Differentiation of tumor

- **Differentiation: the extent to which neoplastic cells resemble comparable normal cells, both morphologically and functionally**
- **Anaplasia: lack of differentiation (tumor parenchyma resembles the tissues of embryonal organs)**

# Grading and differentiation of tumors

- Grade I: well differentiated tumor
  - Grade II: moderately differentiated tumor
  - Grade III: poorly differentiated tumor
  - Grade IV: undifferentiated/anaplastic tumor
- \* High grade tumors associated with poor prognosis.

# Metastases

- Benign tumors do not metastasize
  - Invasiveness of malignant tumor enables metastatic spreading
- 
- Three pathways of metastatic spreading:
    1. Hematogenous spread
    2. Lymphatic spread (especially in carcinomas; sentinel lymph node)
    3. Direct seeding of body cavities or surfaces (implantation on serous surfaces (peritoneum, pleura, pericardium), on mucosal layers of tubular organs , within joint space, in subarachnoid space, ....)



# Risk factors of cancer

- Genetic predisposition to cancer
- Aging
- Lifestyle (tabacco, diet and nutrition, alcohol, sexual and reproductive behaviors, hormonal exposure)
- Occupational or environmental exposure to different carcinogens
- Stress, immune defficiency

# Genetic predisposition to cancer

- AD inherited cancer syndromes (inherited mutation in a single allele of a tumor suppressor gene; the second hit in somatic cells):
  1. *RB tumor suppressor gene* (childhood retinoblastoma)
  2. *APC tumor suppressor gene* (familial adenomatous polyposis)
  3. *p53 tumor suppressor gene* (Li-Fraumeni syndrome)(MEN 1, 2; NF1,2; p16; BRCA1, 2; VHL; Peutz-Jeghers sy,....)
  
- Defective DNA repair syndromes (AD)  
(hereditary nonpolypoid colon cancer (Lynch sy); *MSH2, MSH6, MLH1*)
  
- Familial cancer (breast, pancreas, ovary)
  
- AR inherited cancer syndromes (defective DNA repair, genetic instability; Fanconi anemia, ataxia teleangiectasia, xeroderma pigmentosum,...)
  
- Interactions between genetic and epi-genetic factors


# Nonhereditary predisposing conditions

- Chronic inflammation and cancer
- Precancerous conditions
  - Adenomatous polyps of colon
  - Intraepithelial neoplasia (IN)/dysplasia  
(CIN (cervical), VIN (vulvar), PanIN (pancreatic), PIN (prostatic))
  - Atypical ductal or lobular hyperplasia in breast


# Dysplasia

- In epithelia
- A loss of uniformity of the individual cells as well as loss in their architectural orientation
- Low grade *vs* high grade dysplasia; low grade dysplasia often reversible, high grade dysplasia with a high risk of progression into invasive cancer
- Intraepithelial neoplasia/dysplasia = almost synonyms
- High grade dysplastic changes involving the entire thickness of the epithelium = preinvasive neoplasm = *carcinoma in situ*

# High grade dysplasias/in situ carcinomas



**HG dysplasia/carcinoma in situ in bronchi:** dysplasia in metaplastic squamous epithelium in bronchi



**CIN III :** cervical intraepithelial neoplasia, high grade, in **metaplastic squamous epithelium in endocervical gland**

# Relationship between inflammation and cancer: increased risk of cancer in chronic inflammation.

- IBD (idiopathic bowel disease) – colorectal cancer
- *Helicobacter pylori* chronic gastritis – gastric cancer
- chronic viral hepatitis – hepatocellular carcinoma
- reflux esophagitis (Barret's esophagus) – esophageal carcinoma
- liver fluke infection – cholangiocellular carcinoma
- chronic pancreatitis (both sporadic and hereditary)– pancreatic cancer

# Histogenetic classification of tumors

- Epithelial tumors
- Mesenchymal tumors
- Neuroectodermal tumors
- Germ cell tumors
- Mixed tumors

# Principal characteristics of carcinomas and sarcomas


Feature	Carcinoma	Sarcoma
<b>Origin</b>	Epithelium	Connective/mesenchymal tissue
<b>Behaviour</b>	Malignant	Malignant
<b>Frequency</b>	Common	Relatively rare
<b>Preferred route of metastasis</b>	Lymph (into lymph nodes)	Blood (into liver, bones, brain, .....)
<b>In situ phase</b>	Yes	No
<b>Age group</b>	Usually over 50 years	Usually bellow 50 years




# Epithelial tumors

<b>Epithelium</b>	<b>Benign</b>	<b>Malignant</b>
Squamous	Squamous cell papilloma	Squamous cell carcinoma
Transitional	Transitional cell papilloma	Transitional cell carcinoma
Basal cell	Basal cell papilloma	Basal cell carcinoma
Glandular	Adenoma	Adenocarcinoma

# Carcinomas



Squamous cell carcinoma




Papillocarcinoma

# Polyps of large intestine




Adenomatous polyps of large intestine




Tubular adenoma, low grade dysplasia

# Adenocarcinomas



Adenocarcinoma, intestinal type



Adenocarcinoma – gelatinous, mucinous

<b>Tissue of origin</b>	<b>Benign</b>	<b>Malignant</b>
Smooth muscle	Leiomyoma	Leiomyosarcoma
Striated muscle	Rhabdomyoma	Rhabdomyosarcoma
Adipose tissue	Lipoma	Liposarcoma
Blood vessels	Angioma	Angiosarcoma
Bone	Osteoma	Osteosarcoma
Cartilage	Chondroma	Chondrosarcoma
Soft tissues		Synovial sarcoma
Mesothelium	Benign mesothelioma	Malignant mesothelioma

+ hematological malignancies: leukemias and lymphomas



# Neuroectodermal tumors

- Tumors of central nervous system (CNS)
- Tumors of peripheral nervous system (PNS)
- Tumors of autonomous nervous system (ANS)  
(parasympathetic and sympathetic)
- Melanocytic tumors

# Classification of neuroectodermal tumors


Cell of origin	Tumor
Glial cells	Astrocytoma (both low grade and high grade) Oligodendroglioma (both low grade and high grade) Glioblastoma (Ependymoma)
Primitive neuroectodermal cells	Medulloblastoma (CNS) Neuroblastoma (PNS) Retinoblastoma
Arachnoidal cells	Meningioma
Nerve sheath cells	Schwannoma, neurofibroma Malignant schwannoma, neurofibrosarcoma
ANS	Paragangliomas, chemodectomas, pheochromocytoma
Pigmented cells/melanocytes	Nevus Malignant melanoma

# Glioblastoma multiforme









# Oligodendrogliom



# Neurinom (Schwannom, neurilemmom)



# Malignant melanoma



# Germ cell tumors

- Derived from germ cells
- Somatic differentiation (teratomas – mature, immature)
- Extrasomatic differentiation (chorioncarcinoma, yolk sack tumor)
- testis, ovary + extragonadal germ cell tumors in mediastinum, retroperitoneum, epiphyseal region , sacrococcygeal localisation,...

# Histogenesis of germ cell tumors

Differentiation of primitive cell along the gonadal line  
(gonocyte, spermatogonia), without developed differentiation potencies  
- **Seminoma**

**Primitive germ cell of origin**

**Totipotent cell**

Undifferentiated cell  
- **Embryonal carcinoma**

Extraembryonally differentiated  
- **Yolk sack tumor**  
- **Chorioncarcinoma**

Intraembryonally differentiated  
**Teratoma** (mature, immature, with malignant transformation of somatic elements)  
- **(Polyembryoma)**

- Seminoma (dysgerminoma)
- Spermatocytic seminoma
- Embryonal carcinoma
- Yolk sack tumor
- Polyembryoma
- Chorioncarcinoma
- Teratoma (differentiated mature, differentiated immature, with malignant transformation)
- **Mixed germ cell tumor** (40 %)
- *Oncomarkers*: aFP, hCG, hPL, PLAP, CEA, LDH (detection in serum and/or tissues; diagnostics and monitoring of patients during/after a treatment)

# Germ cell tumors characteristics

tumor	age	structure	oncomarker
<b>Seminoma</b>	40-50	Solid, polygonal clear cells, stromal lymphocytic infiltration.	10 % hCG
<b>Embryonal carcinoma</b>	20-30	Undifferentiated, pleiomorphic cells in sheets, solid, tubullary and papillary; necroses	90 % hCG and/or aFP
<b>Yolk sack tumor</b>	3	Poorly differentiated cells, broad spectrum arrangement of cuboidal and columnar cells, glomeruloid formation	90 % aFP
<b>Chorioncarinoma</b>	20-30	Cytotrophoblast and syncytiotrophoblast without villous formation, haemorrhage, necroses	100 % hCG
<b>Teratoma</b>	*	Tissues of 3 germ layers in various stage of differentiation	50 % hCG and/or aFP
<b>Mixed tumors</b>	15-30	Variable presence of different components; e. g. teratoma+embryonal carcinoma	90 % hCG and/or aFP

\* no age predilection

# Diagnosis of neoplasias

- Early detection and staging important for successful treatment
- The role of screening programs in early diagnostics
- Laboratory values (incl. tumor markers), radiography, endoscopy, isotope scan, CT scan, mammography, MRI and **tissue biopsy (histopathological examination (incl. molecular pathology and genetics) → tumor typing)**



# diagnostic algorithm



clinical signs  
clinical examination

cancer suspicion

yes no

diagnostic imaging techniques  
(x-ray, CT, MRI, ... USG, ...)



suspected cancer

benign tumor,  
pseudotumor

Cancer staging →  
therapy


exploratory biopsy

typing,  
grading,  
staging

malignant  
tumor

yes

no



# Tumor code

- WHO International Classification of Diseases for Oncology (ICD-O): numerical classification and coding system by topography and morphology
- TNM Classification of Malignant Tumors (UICC), AJCC Cancer Staging Manual: coding system of tumor stage
- WHO Classification of Tumours, Pathology and Genetics: histologic classification by organ system

# Tumor code

- Topography (localization) C00.0 – C80.9 (lip – unknown primary localization)
- Subdivision: C34 lung
  - C34.0 main bronchus
  - C34.1 upper lobe
  - ...

# Tumor code

Morphology (histology): digital

- 4 digits – basic histogenetic structure

8070 – tumor of squamous cell

8140 – tumor of glandular cell

# Tumor code

Morphology (histology): digital

■ 5. digit – biologic behaviour

/0 benign (incl. low grade dysplasia)

/1 uncertain, intermediate biologic behaviour, low malignant potential

/2 high grade dysplasia, carcinoma/melanoma in situ

/3 malignant, primary localization

/6 malignant, metastasis

/9 malignant, unknown if primary or metastatic

# Tumor code

Morphology (histology): digital

- 6. digit : grading/differentiation of malignant tumors

1 – 4 well – moderate – low – undifferentiated

8140/0 adenoma

8140/31: well differentiated adenocarcinoma in primary localization

# System of tumor staging

- **TNM (tumor, nodes, metastases)** system used for solid tumors
  - Tumor (T): the size of primary tumor; 0-4
  - Regional lymph nodes (N): regional lymph node involvement; 0-4
  - Metastasis (M): 0 if no distant metastasis present; 1 if distant metastases are present

# Tumor code

- T0 no evidence of primary tumor
- Tis tumor in situ
- T1,T2,T3,T4 increasing size/local extension
- TX primary tumor cannot be assessed
- similarly N0, N1-4, NX
- M0,M1



# Tumor code

Example:


C16.1

M-8140/33




pT3,pN3,pM1

Poorly differentiated adenocarcinoma of stomach fundus with extension into subserosal connective tissue, metastases in 7 or more LN, with distant metastases



# Seminoma





# Germ cell tumors – undifferentiated: embryonal carcinoma



# Germ cell tumors: extraembryonal differentiation




**Choriocarcinoma**




**Yolk sack tumor**

# Germ cell tumors: intraembryonal differentiation



**Mature teratoma**



**Immature teratoma**

# Antineoplastic treatment modalities

- Curative (with intent to cure)
- Palliative (provides symptomatic relief but does not cure)
- Surgical treatment (in solid tumors with a goal of total resection)
- Adjuvant therapies:
  - Irradiation therapy
  - Chemotherapy (especially effective in hematological malignancies)
  - Immunotherapy
  - Hormonal therapy (breast, prostate)
  - Targeted therapy (biologic therapy); individualized, personalized
  - Hematopoietic cell transplantation

\*neoadjuvant therapy

(aims to reduce the size or extent of the cancer before using radical treatment intervention)

# Paraneoplastic syndromes

- **Local effects of tumor growth**

- **+paraneoplastic effects of tumors**

(=signs and symptoms undirect to either primary tumor or its metastases)

# Causes of paraneoplastic syndromes

- Vasoactive tumor products, produced by tumor cells (e.g. serotonin, histamin, catecholamins, prostaglandins,...)
  - Ectopic hormone production by tumor cells (ACTH in small cell lung carcinoma,..)
  - Osteolytic skeletal metastases causing hypercalcaemia
  - Unidentified tumor products or circulating immune complexes (vasculitis, nephritis,...)
  - Production of autoantibodies by tumor cells (paraneoplastic polymyositis, myastenic syndrome, scleroderma,...)
- \* musculoskeletal, neurologic and cutaneous manifestations are often in paraneoplastic syndromes



*Thank you for your attention.....*